Posts Tagged: series A financing
Notch Therapeutics Raises $85M Series A Financing
TIAP portfolio company Notch Therapeutics has announced one of the largest Series A financing rounds in the history of Canadian biotech. We are proud to say that we were there from the start in 2017 when TIAP received the technology disclosure from Dr. Zuniga-Pflucker via our Member, Sunnybrook Health Sciences Centre, and then again when we teamed up with CCRM and Dr. Peter Zandstra of University of Toronto, another one of our Members. TIAP was an early seed investor and acknowledges ...
Read more
Zucara Therapeutics Announces US$21M Series A Financing
– Proceeds to Fund Development of ZT-01 Through Phase 2 Clinical Trials –
– Series A Financing led by the Perceptive Xontogeny Venture Fund –
TORONTO, March 31, 2020 (GLOBE NEWSWIRE) -- Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has closed a US$21 million Series A Financing led by the Perceptive Xontogeny Venture Fund (“PXV Fund”).
The proceeds from the financing will fund Phase 1 and ...
Read more
BlueDot profiled in Toronto Star for anticipating Zika virus spread
BlueDot, a Canadian company that helps decision-makers prepare for and response to infectious disease outbreaks, was profiled in the Toronto Star for their work in tracking the Zika virus.
The company, founded by Dr. Kamran Khan, was spun-off from St. Michael's Hospital in partnership with MaRS Innovation. The company raised a Series A with Horzions Ventures in 2015.
Here's an excerpt from Kate Allen's article:
Wayne Gretzky may be an unlikely inspiration for an infectious disease researcher. Yet here Dr. Kamran Khan is, on ...
Read more
ScarX Therapeutics closes $2 million Series A financing
Canadian biotech company developing ground-breaking therapeutic designed to minimize dermal scarring (fibrosis)
TORONTO (February 16, 2016) — ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis), has closed a $2 million Series A financing. The company will complete a Phase I clinical trial of its lead candidate, SCX-001, in human volunteers, with the eventual goal of creating better functional and cosmetic patient outcomes.
This announcement was covered in TechVibes, BetaKit, Biotechnology Focus, PEHub, Finsmes, and StartupHere Toronto.
SCX-001 is the ...
Read more
Accel-Rx and BDC Capital make second portfolio investment in ScarX Therapeutics
MaRS Innovation portfolio company completing Phase 1 human clinical trial of drug to prevent dermal scarring
VANCOUVER (February 16, 2016) — Accel-Rx Health Sciences Accelerator (Accel-Rx), a Centre of Excellence for the Commercialization of Research (CECR), and its partner BDC Capital today announced their second joint investment in ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis).
Accel-Rx and BDC Capital, and other investors including MaRS Innovation, have invested a total of $2 million in ScarX. This investment will ...
Read more
Dr. Raphael Hofstein in Biotechnology Focus: It’s time to declare an end to Canada’s two research solitudes
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by Dr. Raphael Hofstein, MaRS Innovation's president & CEO, and Elizabeth Monier-Williams, director of marketing and communications.
The article explores the way research focused on discovery and commercialization are often viewed or positioned as competitors within the funding ecosystem and the need to align their goals:
The time of Canada’s French and English solitudes may be past, as Governor General Michaëlle Jean notably stated when she took office ...
Read more
Flybits announces second closing of $4.75M Series A financing
Vodafone expands Toronto-based company’s global partners to advance mobile platform offerings
TORONTO, April 28, 2015 - Vodafone, one of the world’s largest global mobile carriers, has led a second closing of Flybits’ Series A round through Vodafone Ventures. The announcement builds on Flybits’ previously announced Series A financing in August 2014, which was led by Robert Bosch Venture Capital and Trellis Capital.
This announcement was covered in the Financial Post, TechVibes, PE HUB and BetaKit.
As an innovative software-as-a-service (SaaS) company, Flybits enables consumer-focused ...
Read more
ChipCare closes oversubscribed $5 million series A financing
With lead investment from Puffin Partners, the Ontario, Canada-based company is taking lifesaving blood-testing technology to low- and middle-income countries
TORONTO, March 3, 2015 — ChipCare Corporation, a University of Toronto start-up company commercializing a handheld, blood-testing platform for HIV and other infectious and non-communicable diseases has closed a $5.045 million Series A financing to bring its first-generation product to market while further developing the platform’s next generation products.
The Wall Street Journal's Venture Capital Dispatch blog, Yonge Street Media, BetaKit and PEHub ...
Read more
BioCentury features ScarX Therapeutics as emerging company
ScarX Therapeutics, a MaRS Innovation start-up company from the Hospital for Sick Children, was featured in "Scars Defaced," a BioCentury emerging company profile by Michael J. Haas.
The profile is available to BioCentury subscribers on their website (paywall in place).
Here's a short excerpt:
ScarX Corp. has reformulated a generic analgesic that is marketed primarily in Europe into a topical cream that patients can self-administer
after surgery to prevent scarring. The company expects cosmetic and reconstructive surgeons to be early adopters of its topical nefopam, ...
Read more